Emergent BioSolutions (EBS) EPS (Weighted Average and Diluted) (2010 - 2026)

Emergent BioSolutions' EPS (Weighted Average and Diluted) history runs 17 years deep, the most recent figure standing at $0.07 for Q1 2026.

• In Q1 2026, EPS (Weighted Average and Diluted) fell 94.12% year-over-year to $0.07; the TTM figure through Mar 2026 stood at -$0.2 (up 92.59% YoY), while the FY2025 annual figure was $0.93, up 125.83% from the prior year.
• EPS (Weighted Average and Diluted) was $0.07 for Q1 2026 at Emergent BioSolutions, up from -$0.96 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.06 in Q3 2024 to a low of -$5.38 in Q2 2024.
• Historically, EPS (Weighted Average and Diluted) has averaged -$1.28 across 5 years, with a median of -$0.88 in 2023.
• The sharpest annual moves came in 2022 and 2025: EPS (Weighted Average and Diluted) plunged 10500.0% in 2022, then surged 600.0% in 2025.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.34 in 2022, then soared by 34.33% to -$0.88 in 2023, then jumped by 35.23% to -$0.57 in 2024, then plunged by 68.42% to -$0.96 in 2025, then surged by 107.29% to $0.07 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.07 (Q1 2026), -$0.96 (Q4 2025), and $0.91 (Q3 2025), per Business Quant data.